Atlantis Glory Inc
OTC:AGLY
Atlantis Glory Inc
OTC:AGLY
Price:
0.017
USD
Market Cap:
$10.3m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Atlantis Glory Inc
OTC:AGLY
|
CN |
|
E
|
European Healthcare Acquisition & Growth Company BV
AEX:EHCS
|
DE |
|
GHT Co Ltd
SZSE:300711
|
CN |
|
BabyTree Group
HKEX:1761
|
CN |
|
Kothari Sugars and Chemicals Ltd
NSE:KOTARISUG
|
IN |
|
C
|
Coraza Integrated Technology Bhd
KLSE:CORAZA
|
MY |
|
ASX Ltd
ASX:ASX
|
AU |
|
T
|
Tus Pharmaceutical Group Co Ltd
SZSE:000590
|
CN |
|
GBS Software AG
XETRA:INW1
|
DE |
|
F
|
Fintech SA
WSE:FTH
|
PL |
Income Statement
Earnings Waterfall
Atlantis Glory Inc
Atlantis Glory Inc
Income Statement
Atlantis Glory Inc
Atlantis Glory Inc
Currency: USD
| Dec-2019 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||||||
| Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
| Gross Profit | |||||||||||||||||||||
| Cost of Revenue |
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Gross Profit |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
| Operating Income | |||||||||||||||||||||
| Operating Expenses |
(4)
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
8
|
8
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
|
| Selling, General & Administrative |
(2)
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
|
| Research & Development |
(2)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Operating Expenses |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
8
|
8
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Operating Income |
(4)
N/A
|
0
N/A
|
0
N/A
|
(0)
N/A
|
(0)
N/A
|
(0)
-11%
|
(0)
-3%
|
(0)
+88%
|
(0)
-50%
|
8
N/A
|
8
N/A
|
(0)
N/A
|
(0)
+59%
|
(0)
+9%
|
(0)
+10%
|
(0)
-70%
|
(0)
+0%
|
(0)
+0%
|
(0)
-1%
|
(0)
+3%
|
|
| Pre-Tax Income | |||||||||||||||||||||
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
8
|
8
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Other Income |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Pre-Tax Income |
(4)
N/A
|
0
N/A
|
0
N/A
|
(0)
N/A
|
(0)
N/A
|
(0)
-11%
|
(0)
-3%
|
8
N/A
|
8
0%
|
8
N/A
|
8
N/A
|
(0)
N/A
|
(0)
+59%
|
(0)
+9%
|
(0)
+10%
|
(0)
-70%
|
(0)
+0%
|
(0)
+0%
|
(0)
-1%
|
(0)
+3%
|
|
| Net Income | |||||||||||||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Income from Continuing Operations |
(4)
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
8
|
8
|
8
|
8
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
|
| Net Income (Common) |
(4)
N/A
|
0
N/A
|
0
N/A
|
(0)
N/A
|
(0)
N/A
|
(0)
-11%
|
(0)
-3%
|
8
N/A
|
8
0%
|
8
N/A
|
8
N/A
|
(0)
N/A
|
(0)
+59%
|
(0)
+9%
|
(0)
+10%
|
(0)
-70%
|
(0)
+0%
|
(0)
+0%
|
(0)
-1%
|
(0)
+3%
|
|
| EPS (Diluted) |
-0.01
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0.01
N/A
|
0.01
N/A
|
0.01
N/A
|
0.01
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
Switch to:
Switch to:
See Also
Discover More
